Angiotensin II

Extended indication	Hypotension in adults with septic or other distributive shock
Therapeutic value	No judgement
Registration phase	Registration application pending

Product

Active substance	Angiotensin II
Domain	Cardiovascular diseases
Reason of inclusion	New medicine (specialité)
Main indication	Other medication for cardiovascular diseases
Extended indication	Hypotension in adults with septic or other distributive shock
Proprietary name	Giapreza
Manufacturer	La Jolla
Mechanism of action	Receptor agonist
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)
Additional remarks	Angiotensin-type-1-receptor-agonists

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
Submission date	July 2018
Expected Registration	August 2019
Orphan drug	No
Registration phase	Registration application pending
Additional remarks	In Juli op de lijst van de EMA (Medicines Under Evaluation).

Therapeutic value	No judgement
Substantiation	De inschatting is dat dit geneesmiddel niet veel gebruikt gaat worden in Nederland.
Dosage per administration	starten met 20 ng/ kg/min voor 3 uur

Patient volume	< 15,000 Market share is generally not included unless otherwise stated.
References	SPS
Additional remarks	In Amerika 300.000 personen die in aanmerking zouden komen voor het geneesmiddel, teruggerekend naar Nederland zou dat gaan 15.000 patiënten.

Patient volume

< 15,000

Market share is generally not included unless otherwise stated.

References

SPS

Additional remarks

In Amerika 300.000 personen die in aanmerking zouden komen voor het geneesmiddel, teruggerekend naar Nederland zou dat gaan 15.000 patiënten.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.